Sarah JS Glickman
Known title: Chief Financial OfficerCIK: 0001749338
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
Transaction History
| CRTO | ▼ Sell | Open Market | 6,285 | $108K | 8/6/2026 | View on chart |
| CRTO | ▼ Sell | Other | 430,897 | $0 | 7/29/2026 | View on chart |
| CRTO | ▲ Buy | Grant | 430,897 | $0 | 7/29/2026 | View on chart |
| ATR | ▲ Buy | Grant | 151 | $0 | 7/16/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 982 | $18K | 6/1/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,313 | $22K | 5/26/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,152 | $20K | 5/26/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,326 | $0 | 5/6/2026 | View on chart |
| CRTO | ▲ Buy | Grant | 83,502 | $0 | 3/13/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,943 | $36K | 3/3/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 18,304 | $329K | 3/2/2026 | View on chart |
| CRTO | ▲ Buy | Grant | 17,284 | $0 | 2/26/2026 | View on chart |
| CRTO | ▲ Buy | Grant | 4,915 | $0 | 2/26/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,541 | $26K | 2/24/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,796 | $47K | 2/23/2026 | View on chart |
| CRTO | ▼ Sell | Open Market | 3,982 | $78K | 11/24/2025 | View on chart |
| CRTO | ▼ Sell | Open Market | 3,981 | $96K | 8/25/2025 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,520 | $40K | 5/27/2025 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,465 | $64K | 5/23/2025 | View on chart |
| ATR | ▲ Buy | Grant | 1,069 | $0 | 5/7/2025 | View on chart |
| CRTO | ▲ Buy | Grant | 32,456 | $0 | 2/28/2025 | View on chart |
| CRTO | ▲ Buy | Grant | 38,724 | $0 | 2/28/2025 | View on chart |
| CRTO | ▼ Sell | Open Market | 17,883 | $721K | 2/25/2025 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,520 | $61K | 11/25/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 5,442 | $221K | 10/23/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,519 | $75K | 8/26/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 5,496 | $250K | 7/23/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 1,535 | $60K | 5/24/2024 | View on chart |
| ATR | ▲ Buy | Grant | 1,113 | $0 | 5/1/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 5,504 | $195K | 4/23/2024 | View on chart |
| CRTO | ▲ Buy | Grant | 39,717 | $0 | 3/1/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 9,653 | $316K | 2/26/2024 | View on chart |
| CRTO | ▲ Buy | Grant | 52,966 | $0 | 2/23/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 3,622 | $90K | 1/23/2024 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,752 | $77K | 10/23/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,752 | $77K | 10/23/2023 | View on chart |
| ATR | ▲ Buy | Grant | 894 | $0 | 10/17/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,710 | $88K | 7/24/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,751 | $90K | 7/24/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,521 | $76K | 4/24/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,521 | $76K | 4/24/2023 | View on chart |
| CRTO | ▲ Buy | Grant | 46,600 | $0 | 2/23/2023 | View on chart |
| CRTO | ▲ Buy | Grant | 24,661 | $0 | 2/23/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,827 | $82K | 1/23/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 2,827 | $82K | 1/23/2023 | View on chart |
| CRTO | ▼ Sell | Open Market | 25,510 | $664K | 10/24/2022 | View on chart |
| CRTO | ▼ Sell | Open Market | 28,224 | $735K | 10/24/2022 | View on chart |
| CRTO | ▲ Buy | Grant | 36,808 | $0 | 2/24/2022 | View on chart |
| CRTO | ▲ Buy | Grant | 110,327 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRTO: CVS settlement claim deadline a month away
A recent Yahoo article notes that the deadline to file a claim in the CVS settlement is about one month away. The matter does not involve Criteo directly, so the news is unlikely to change the company's fundamentals. With CRTO currently trading near its recent support level, broader market sentiment could still influence price movement.
CRTO: CVS settlement claim deadline a month away. A recent Yahoo article notes that the deadline to file a claim in the CVS settlement is about one month away. The matter does not involve Criteo directly, so the news is unlikely to change the company's fundamentals. With CRTO currently trading near its recent support level, broader market sentiment could still influence price movement.